Horn & Co. represented the investors in ArtsAvit’s financing round, led by Pontifax, Arkin Holdings and Merck Ventures
ARTSaVIT, a company developing a cancer drug, has completed a $6.3 financing round. The company is slated to enter the Merck Ventures incubator in Yavne operating under Inter-Lab, the Israeli drug development division of German company Merck Serono. Mori Arkin’s Arkin Bio Ventures led the round together with the Pontifax fund, with participation from Merck Ventures.
Yuval Horn (Picture) and Ohad Mamann of Horn & Co. represented the investors
Law Firms: Horn & Co. Law;